Agaricus blazei Murill enhances doxorubicin-induced apoptosis in human hepatocellular carcinoma cells by NFκB-mediated increase of intracellular doxorubicin accumulation

International Journal of Oncology

Volumn 38, Issue 2, 2011, Pages 401-408

  Lee, Jong Seok ^a   Hong, Eock Kee ^a  

^a Kangwon National University   (South Korea)

Author keywords

Agaricus blazei; Apoptosis; Doxorubicin; Hepatocellular carcinoma; NF B

Indexed keywords

AGARICUS BLAZEI EXTRACT; DOXORUBICIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENTIATION; DRUG SENSITIVITY; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MOLECULAR MECHANICS; PRIORITY JOURNAL;

AGARICUS; ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CELL NUCLEUS; CELL PROLIFERATION; DOXORUBICIN; DRUG SYNERGISM; HUMANS; LIVER NEOPLASMS; NF-KAPPA B; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SUBCELLULAR FRACTIONS;

EID: 78651257641     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2010.852     Document Type: Article

References (40)

1. Falkson G, MacIntyre JM and Moertel CG: Primary liver cancer. Cancer 54: 977-980, 1994.
2. Llovet JM: Updated treatment approach to hepatocellular carcinoma. J Gastroenterol 40: 225-235, 2005.
3. Hochster HS, Green MD, Speyer J, Fazzini E, Blum R and Muggia FM: 4'Epidoxorubicin (epirubicin): activity in hepatocellular carcinoma. J Clin Oncol 3: 1535-1540, 1985.
4. Kruh GD and Goldstein LJ: Doxorubicin and multidrug resistance. Curr Opin Oncol 5: 1029-1034, 1993.
5. Gangadharan C, Thoh M and Manna SK: Inhibition of constitutive activity of nuclear transcription factor kappaB sensitizes doxorubicin-resistant cells to apoptosis. J Cell Biochem 107: 203-213, 2009.
6. Liu P, Kimmoun E, Legrand A, Sauvanet A, Degott C, Lardeux B and Bernuau D: Activation of NF-kappaB, Ap-1 and STAT transcription factor is a frequent and early event in human hepatocellular carcinomas. J Hepatol 37: 63-71, 2002.
7. Nakanishi C and Toi M: Nuclear factor-κB inhibitors as sensitizers to anticancer drugs. Nat Rev Cancer 5: 297-309, 2005.
8. Pahl HL: Activators and target genes of Rel/NF-κB transcription factors. Oncogene 18: 6853-6866, 1999.
9. Siebenlist U, Franzoso G and Brown K: Structure, regulation and function of NF-kappaB. Annu Rev Cell Biol 10: 405-455, 1994.
10. Mori N, Yamada Y, Ikeda S, Yamasaki Y, Tsukasaki K, Tanaka Y, Tomonaga M, Yamamoto N and Fujii M: Bay 11-7082 inhibits transcription factor NF-κB and induces apoptosis of HTLV-Iinfected T-cell lines and primary adult T-cell leukemia cells. Blood 100: 1828-1834, 2002.
11. Lin YZ, Yao SY, Veach RA, Torgerson TR and Hawiger J: Inhibition of nuclear translocation of transcription factor NF-kappaB by a synthetic peptide containing a cell membrane-permeable motif and nuclear localization sequence. J Biol Chem 270: 14255-14258, 1995.
12. Novak M and Vetvicka V: Beta-glucans, history, and the present: Immunomodulatory aspects and mechanisms of action. J Immunotoxicol 5: 47-57, 2008.
13. Kobayashi H, Yoshida R, Kanada Y, Fukuda Y, Yagyu T, Inagaki K, Kondo T, Kurita N, Suzuki M, Kanayama N and Terao T: Suppressing effects of daily oral supplementation of beta-glucan extracted from Agaricus blazei Murill on spontaneous and peritoneal disseminated metastasis in mouse model. J Cancer Res Clin Oncol 131: 527-538, 2005.
14. Chihara G, Maeda Y, Hamuro J, Sasaki T and Fukuoka F: Inhibition of mouse sarcoma 180 by polysaccharides from Lentinus edodes (Berk.) sing. Nature 222: 687-688, 1969.
15. Wan JM, Sit WH and Louie JC: Polysaccharopeptide enhances the anticancer activity of doxorubicin and etoposide on human breast cancer cells ZR-75-30. Int J Oncol 32: 689-699, 2008.
16. Ng TB and Wang HX: Pharmacological actions of Cordyceps, a prized folk medicine. J Pharm Pharmacol 57: 1509-1520, 2005.
17. Jin CY, Choi YH, Moon DO, Park C, Park YM, Jeong SC, Heo MS, Lee TH, Lee JD and Kim GY: Induction of G2/M arrest and apoptosis in human gastric epithelial AGS cells by aqueous extract of Agaricus blazei. Oncol Rep 16: 1349-1355, 2006.
18. Yu CH, Kan SF, Shu CH, Lu TJ, Sun-Hwang L and Wang PS: Inhibitory mechanisms of Agaricus blazei Murill on the growth of prostate cancer in vitro and in vivo. J Nutr Biochem 20: 753-764, 2009.
19. Ghobrial IM, Witzig TE and Adjei AA: Targeting apoptosis pathways in cancer therapy. CA Cancer J Clin 55: 178-194, 2005.
20. Saraste A and Pulkki K: Morphologic and biochemical hallmarks of apoptosis. Cardiovasc Res 45: 528-537, 2000.
21. Scorrano L: Opening the doors to cytochrome c: Changes in mitochondrial shape and apoptosis. Int J Biochem Cell Biol 41: 1875-1883, 2009.
22. Cohen GM: Caspases: the executioners of apoptosis. Biochem J 326: 1-16, 1997.
23. Wu X, Kakehi Y, Mizutani Y, Kamoto T, Kinoshita H, Isogawa Y, Terachi T and Ogawa O: Doxorubicin enhances TRAIL-induced apoptosis in prostate cancer. Int J Oncol 20: 949-954, 2002.
24. Pan YY, Xu SP, Jia XY, Xu HQ, Zhang Y, Rui LX and Wei W: Combination of cyclooxygenase-2 inhibitor and doxorubicin increases the growth inhibition and apoptosis in human hepatocellular carcinoma cells. Exp Oncol 29: 23-29, 2007.
25. Collins L, Zhu T, Guo J, Xiao ZJ and Chen CY: Phellinus linteus sensitises apoptosis induced by doxorubicin in prostate cancer. Br J Cancer 95: 282-288, 2006.
26. Pinmai K, Chunlaratthanabhorn S, Ngamkitidechakui C, Soonthornchareon N and Hahnvajanawong C: Synergistic growth inhibitory effects of Phyllanthus emblica and Terminalia bellerica extracts with conventional cytotoxic agents: Doxorubicin and cisplatin against human hepatocellular carcinoma and lung cancer cells. World J Gastroenterol 14: 1491-1497, 2008.
27. Lee JS, Kwon JS, Yun JS, Pahk JW, Shin WC, Lee SY and Hong EK: Structural characterization of immunostimulating polysaccharide from cultured mycelia of Cordyceps militaris. Carbohydr Polym 80: 1011-1017, 2010.
28. Lee JS, Cho JY and Hong EK: Study on macrophage activation and structural characteristics of purified polysaccharides from the liquid culture broth of Hericium erinaceus. Carbohydr Polym 78: 162-168, 2009.
29. Lee JS and Hong EK: Hericium erinaceus enhances doxorubicin-induced apoptosis in human hepatocellular carcinoma cells. Cancer Lett: doi:10.1016/j.canlet.2010.05.006 (E-pub ahead of print). 2010.
30. Feng G and Kaplowitz N: Colchicine protects mice from the lethal effects of an agonistic anti-Fas antibody. J Clin Invest 105: 329-339, 2000.
31. van Wijngaarden J, van Beek E, van Rossum G, van der Bent C, Hoekman K, van der Pluijm G, van der Pol MA, Broxterman HJ, van Hinsbergh VW and Lowik CW: Celecoxib enhances doxorubicin-induced cytotoxicity in MDA-MB231 cells by NF-κB-mediated increase of intracellular doxorubicin accumulation. Eur J Cancer 43: 433-442, 2007.
32. Thornberry NA and Lazebnik Y: Caspases: enemies within. Science 281: 1312-1316, 1998.
33. Hannun YA: Apoptosis and the dilemma of cancer chemotherapy. Blood 89: 1845-1853, 1997.
34. Los M, Herr I, Friesen G, Fulda S, Schulze-Osthoff K and Lipkowitz S: Cross-resistance of CD95 and drug-induced apoptosis as a consequence of deficient activation of caspases (ICE/Ced-3 proteases). Blood 90: 3118-3129, 1997.
35. Gross A, McDonnell JM and Korsmeyer SJ: Bcl-2 family members and the mitochondria in apoptosis. Genes Dev 13: 1899-1911, 1999.
36. Schuler M and Green DR: Mechanisms of p53-dependent apoptosis. Biochem Soc Trans 7: 684-688, 2001.
37. Chipuk JE and Green DR: p53's believe it or not: Lessons on transcription-independent death. J Clin Immunol 23: 355-361, 2003.
38. Dimanche-Boitrel MT, Meurette O, Rebillard A and Lacour A: Role of early plasma membrane events in chemotherapy-induced cell death. Drug Resist Updat 8: 5-14, 2005.
39. Deng L, Lin-Lee YC, Claret FX and Kuo MT: 2-Acetylaminofluorene upregulates rat mdr1b expression through generating reactive oxygen species that activate NF-kappa B pathway. J Biol Chem 276: 413-420, 2001.
40. Kuo MT, Liu Z, Wei Y, Lin-Lee YC, Tatebe S, Mills GB and Unate H: Induction of human MDR1 gene expression by 2-acetylaminofluorene is mediated by effectors of the phosphoinositide 3-kinse pathway that activate NF-kappaB signaling. Oncogene 21: 1945-1954, 2002.